CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Stem Cell 100+dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03052491
NCT03052491N/ACompleted
CompareCT.gov

Effects of a Multi-Pathway Dietary Supplement (Stem Cell 100+) on Indices of Health and Life Expectancy

Centagen, Inc.·interventional·Posted Feb 14, 2017·Updated Feb 14, 2017

In Brief

A clinical study evaluating Stem Cell 100+ for Blood Pressure and 8 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years. The objective of the intervention trial is to determine if normal subjects over 35 years of age experience any observable health benefits from the dietary supplement as to their blood pressure, pulse rate, blood cholesterol, lung capacity, stress levels, or self reported changes in markers of overall health and life expectancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Pressure, HDL Low, Stress, Lung Function Decreased, Quality of Life, Energy Supply; Deficiency, Concentration Ability Impaired, Joint Instability, Immune Deficiency
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 14, 2017
Enrollment StartMar 12, 2016
Primary CompletionAug 24, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.4 years ago

Interventions

Stem Cell 100+dietary

Open-Label 10-Component Dietary Supplement